| __timestamp | Incyte Corporation | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 347523000 | 242549000 |
| Thursday, January 1, 2015 | 479514000 | 245098000 |
| Friday, January 1, 2016 | 581861000 | 147600000 |
| Sunday, January 1, 2017 | 1326361000 | 264600000 |
| Monday, January 1, 2018 | 1197957000 | 357900000 |
| Tuesday, January 1, 2019 | 1154111000 | 1182600000 |
| Wednesday, January 1, 2020 | 2215942000 | 357700000 |
| Friday, January 1, 2021 | 1458179000 | 540100000 |
| Saturday, January 1, 2022 | 1585936000 | 322900000 |
| Sunday, January 1, 2023 | 1627594000 | 408000000 |
| Monday, January 1, 2024 | 2606848000 |
Unleashing insights
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Incyte Corporation and United Therapeutics Corporation have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Incyte Corporation has consistently increased its R&D expenses, peaking in 2020 with a staggering 536% increase from 2014. This aggressive investment underscores Incyte's dedication to expanding its drug pipeline and maintaining a competitive edge. In contrast, United Therapeutics Corporation's R&D spending has been more conservative, with a notable spike in 2019, reaching its highest at nearly 400% of its 2014 expenditure.
These trends highlight the diverse approaches within the biotech sector, where strategic R&D allocation can significantly influence a company's market position and innovation trajectory.
R&D Spending Showdown: Takeda Pharmaceutical Company Limited vs United Therapeutics Corporation
Comparing Innovation Spending: Biogen Inc. and Incyte Corporation
United Therapeutics Corporation vs Exelixis, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: United Therapeutics Corporation vs Xenon Pharmaceuticals Inc.
United Therapeutics Corporation vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
United Therapeutics Corporation vs HUTCHMED (China) Limited: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and Veracyte, Inc.
Research and Development: Comparing Key Metrics for Incyte Corporation and Lantheus Holdings, Inc.
Incyte Corporation vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Incyte Corporation vs Mesoblast Limited: Strategic Focus on R&D Spending
Comparing Innovation Spending: Incyte Corporation and Iovance Biotherapeutics, Inc.